GRANT OF PATENT RIGHTS Sample Clauses

GRANT OF PATENT RIGHTS. (1) In consideration for its sponsorship of the research program, Sponsor shall retain an irrevocable, royalty-free, worldwide, nonexclusive license, without the right to sublicense, for Sponsor's own internal research use, under any Princeton-owned Inventions, under any patents or patent applications. (2) Princeton, to the extent it is permitted to do so by its agreements with other government sponsors of research, and the provisions of Public Laws 96-517 and 98-620, grants to Sponsor an exclusive Option to obtain an exclusive worldwide license to any Princeton-owned Inventions and Princeton's right, title and interest under any Jointly-owned Inventions, patents or patent applications, with a right to sublicense upon Princeton's approval, which shall not be unreasonably withheld, on the terms and conditions set forth in the resulting license agreements. Sponsor agrees not to sublicense or assign any such intellectual property to Transcell Technologies Inc., without Princeton's written consent. (3) Such Option with respect to each Invention shall extend for a period commencing on the date the Invention is disclosed to Sponsor through ninety (90) days from the filing date of a patent application disclosing and claiming same. Sponsor may exercise its Option on Princeton-owned and jointly-owned patent applications or patents by providing a written statement to Princeton. Upon exercise of each such Option, Sponsor and Princeton shall have twelve (12) months to negotiate in good faith a royalty-bearing worldwide exclusive license under reasonable royalty terms. During the Option and subsequent negotiation periods, Princeton shall not offer commercial license rights to any third party. At the end of twelve (12) months from the date Sponsor exercises its Option if no license agreement has been signed, Princeton shall be free to negotiate licenses with other parties, and Sponsor shall have no further rights to such Inventions except for those provided for in 7.d.1 herein, and those it retains to any jointly owned Inventions by virtue of its ownership thereof.
Sample 1Sample 2
AutoNDA by SimpleDocs
GRANT OF PATENT RIGHTS. 2.1 License under the JPPLP Patent Rights. Barrier hereby grants to JPPLP the exclusive (even as to Barrier and its Affiliates), royalty-bearing license, with the unrestricted right to grant sublicenses (subject to Section 2.2), under the Patent Rights to make, have made, import, use, sell, offer for sale, and have sold the Itraconazole Product in the Territory.
Sample 1Sample 2
GRANT OF PATENT RIGHTS. 2.1 Barrier's License under the `932 Patent Rights. Subject to Section 2.2, JJCC hereby grants to Barrier the exclusive (even as to JJCC and its Affiliates), royalty-free license with the unrestricted right to grant sublicenses (subject to Section 2.6 and Article 5), under the `932 Patent Rights to (i) import, use, sell, offer for sale, and have sold `932 Products in the `932 Territory and (ii) make and have made `932 Products anywhere in the world to import, use, sell, offer for sale, and have sold `932 Products in the `932 Territory. For avoidance of doubt, there ** Certain information in these exhibits has been omitted and will be filed separately with the Securities and Exchange Commission pursuant to a confidential treatment request. shall be no field-of-use limitation on the license granted pursuant to this Section 2.1(a) regarding indications for which `932 Products may be used. 2.2 JJCC's Retained Rights Under the `932 Patent Rights. JJCC retains all rights under the `932 Patent Rights, including the unrestricted right to grant sublicenses, to (i) import, use, sell, offer for sale, and have sold `932 Products in the JJCC Countries, (ii) make and have made the `932 Products anywhere in the world to import, use, sell, offer for sale, and (iii) have sold such `932 Products in the JJCC Countries and retains the non-exclusive right, including the unrestricted right to grant sublicenses, to make, have made, import, use, sell, offer for sale, and have sold products (other than the Diaper Dermatitis Product) for which JJCC or its Affiliates can show through tangible dated evidence was under development (having at least performed in vivo studies) or marketed by JJCC or such Affiliate prior to the Execution Date. For avoidance of doubt, there shall be no field-of-use limitation on the rights retained under this Section 2.2 regarding indications for which products may be used. 2.3 License Under the `683 Patent Rights. (a) Subject to Sections 2.3(b) and 2.4, JJCC hereby grants to Barrier the exclusive (even as to JJCC and its Affiliates), royalty-free, worldwide license, with the unrestricted right to grant sublicenses (subject to Section 2.6 and Article 5), under the `683 Patent Rights to make, have made, import, use, sell, offer for sale, and have sold `683 Products. For avoidance of doubt, there shall be no field-of-use limitation on the license granted pursuant to this Section 2.3(a) regarding indications for which `683 Products may be used. (b) Barrier's ...
Sample 1Sample 2
GRANT OF PATENT RIGHTS. 2.1 License under the JPPLP Patent Rights. (a) Subject to Section 2.1(b), JPPLP hereby grants to Barrier the exclusive (even as to JPPLP and its Affiliates), royalty-free, worldwide license, with the unrestricted right to grant sublicenses (subject to Section 2.6 and Article 7), under the JPPLP Patent Rights to make, have made, import, use, sell, offer for sale, and have sold JPPLP Products in the Territory in the Field. (b) Barrier's license under Section 2.1(a) and Article 3 shall not include the right to make, have made, import, use, sell, offer for sale, and have sold human dandruff shampoo products in Germany that can be legally sold without a prescription. 2.2 License under the `096 Patent Rights. JPPLP hereby grants to Barrier the exclusive (even as to JPPLP and its Affiliates), royalty-free, worldwide license, with the unrestricted right to grant sublicenses (subject to Section 2.6 and Article 7), under the `096 Patent Rights to make, have made, import, use, sell, offer for sale, and have sold the `096 Product in the Territory in the Field. 2.3 License under the Ketanserin Patent Rights. (a) JPPLP hereby grants to Barrier the exclusive (even as to JPPLP and its Affiliates), royalty-free license, with the unrestricted right to grant sublicenses (subject to Section 2.6 and Article 7), under the Ketanserin Patent Rights to (i) import, use, sell, offer for sale, and have sold, Ketanserin Products in the Ketanserin Territory in the Field, and (ii) make and have made Ketanserin Products anywhere in the world to import, use, sell, offer for sale, and have sold Ketanserin Products in the Ketanserin Territory in the Field. (b) JPPLP retains all rights under the Ketanserin Patent Rights, including the unrestricted right to grant sublicenses, to (i) import, use, sell, offer for sale, and have sold Ketanserin Products in the JPPLP Ketanserin Countries, and (ii) make and have made the Ketanserin Products anywhere in the world to import, use, sell, offer for sale, and have sold such Ketanserin Products in the JPPLP Ketanserin Countries. 2.4 License under the Itraconazole Patent Rights. (a) Subject to Section 2.4(b), JPPLP hereby grants to Barrier the exclusive (even as to JPPLP and its Affiliates), worldwide license, with the unrestricted right to grant sublicenses (subject to Section 2.6 and Article 6), under the Itraconazole Patent Rights to make, ** Certain information in these exhibits has been omitted and will be filed separately with the Securities and Exc...
Sample 1
GRANT OF PATENT RIGHTS. Subject to the terms and conditions of this AGREEMENT, UNIVERSITY hereby grants to LICENSEE and LICENSEE accepts a royalty- free, non-transferrable, non-exclusive license (without the right to sublicense) under the PATENT RIGHTS to make and use the LICENSED SOFTWARE within the LICENSED TERRITORY for use within LICENSED FIELD for a term as set forth in Section 6.01 unless this AGREEMENT shall be sooner terminated according to the terms hereof.
Sample 1

Related to GRANT OF PATENT RIGHTS

  • Grant of Patent License Subject to the terms and conditions of this Agreement, You hereby grant to OIDF and to recipients of software distributed by OIDF a perpetual, worldwide, non- exclusive, no-charge, royalty-free, irrevocable (except as stated in this section) patent license to make, have made, use, offer to sell, sell, import, and otherwise transfer the Work, where such license applies only to those patent claims licensable by You that are necessarily infringed by Your Contribution(s) alone or by combination of Your Contribution(s) with the Work to which such Contribution(s) was submitted. If any entity institutes patent litigation against You or any other entity (including a cross-claim or counterclaim in a lawsuit) alleging that your Contribution, or the Work to which you have contributed, constitutes direct or contributory patent infringement, then any patent licenses granted to that entity under this Agreement for that Contribution or Work shall terminate as of the date such litigation is filed.

  • Enforcement of Patent Rights Oxis, at its sole expense, shall have the right to determine the appropriate course of action to enforce Licensed Patent Rights or otherwise xxxxx the infringement thereof, to take (or refrain from taking) appropriate action to enforce Licensed Patent Rights, to defend any declaratory judgments seeking to invalidate or hold the Licensed Patent Rights unenforceable, to control any litigation or other enforcement action and to enter into, or permit, the settlement of any such litigation, declaratory judgments or other enforcement action with respect to Licensed Patent Rights, in each case in Oxis' own name and, if necessary for standing purposes, in the name of Licensor and shall consider, in good faith, the interests of Licensor in so doing. If Oxis does not, within one hundred twenty (120) days of receipt of notice from Licensor, xxxxx the infringement or file suit to enforce the Licensed Patent Rights against at least one infringing party in the Territory, Licensor shall have the right to take whatever action it deems appropriate to enforce the Licensed Patent Rights; provided, however, that, within thirty (30) days after receipt of notice of Licensor's intent to file such suit, Oxis shall have the right to jointly prosecute such suit and to fund up to one-half (½) the costs of such suit. The party controlling any such enforcement action shall not settle the action or otherwise consent to an adverse judgment in such action that diminishes the rights or interests of the non-controlling party without the prior written consent of the other party. All monies recovered upon the final judgment or settlement of any such suit to enforce the Licensed Patent Rights shall be shared, after reimbursement of expenses, in relation to the damages suffered by each party. If Oxis does not receive sufficient monies from a final judgment or settlement to cover its expenses for such suit, Oxis shall have the right to credit up to fifty percent (50%) of such expenses against any royalties or other fees owing by Oxis pursuant to Section 4 above.

  • Licensed Patent Rights The term “Licensed Patent Rights” shall mean rights arising out of or resulting from:

  • Patent Rights The State and the U. S. Department of Transportation shall have the royalty free, nonexclusive and irrevocable right to use and to authorize others to use any patents developed by the Engineer under this contract.

  • Licensed Patents 9.1.1 Oculis shall be responsible for and shall have the exclusive right with respect to, the preparation, filing, prosecution, protection, maintenance and enforcement of all Patent Rights in respect of the Licensed Technology in its discretion using its patent counsel. Oculis shall consult with Accure with respect thereto, supply Accure with a copy of the application as filed, together with notice of its filing date and serial number; and keep Accure advised of the status of actual and prospective Patent Right filings, including office actions, and keep Accure informed about and provide copies of all the relevant information exchanged between Oculis and the different Industrial or Intellectual Property Registration Offices regarding the prosecution, maintenance, defense and enforcement of the Licensed Patents. The cost and expense of filing, prosecuting, maintaining and enforcing all Licensed Patents shall be borne by Oculis. Accure shall, and hereby procures its personnel will, provide all requested information and perform all acts reasonably requested by Oculis in connection with the prosecution, maintenance, defense or enforcement of the Licensed Technology. Without limiting the foregoing, Accure and its Affiliates may not file for further Patent Rights relating to Licensed Technology. 9.1.2 Should Oculis not be interested in the prosecution, defense and maintenance of any or all of the Licensed Patents, and/or Xxxxxx decides not to pay all reasonable and necessary expenses with respect to the prosecution, defense or maintenance of any Licensed Patent before any upcoming deadline, Oculis shall give reasonable advance notice to Accure (no less than [***]), and subsequent to such notice Accure shall act as it deems appropriate in connection with the prosecution, defense and maintenance of the Licensed Patents at their discretion and at their own cost. As from such notification, Oculis shall not be responsible for costs associated with such Licensed Patents, and, where such notification is provided following such time as Xxxxxx assumes responsible for performing patenting matters as set forth above, Oculis shall not be responsible for the preparation, filing, prosecution, protection and maintenance of the mentioned Licensed Patents and such Patent Rights shall cease to be Licensed Patents and the provisions of Agreement shall be of no further effect with respect to such patent and/or country of the Territory.

  • Joint Patent Rights If not already established under the Research Collaboration Agreement, prior to either Party filing any Patent Right disclosing Joint Program Technology or Joint Probody Platform Improvements, the Parties shall establish a patent committee (the “Patent Committee”) comprised of at least one (1) representative of each Party for the purpose of facilitating the preparation, filing, prosecution, maintenance and defense of Joint Patent Rights. As agreed upon by the Parties, meetings of the Patent Committee may be face-to-face or may be conducted by teleconferences or videoconferences, from time to time as needed. The Patent Committee will be the forum through which the Parties coordinate their respective obligations to each other described in Sections 5.2.2 and 5.2.3 hereof and in this Section. In the event the Parties conceive or generate any Joint Program Technology or Joint Probody Platform Improvements, the Parties shall promptly meet to discuss and determine, based on mutual consent, whether to seek patent protection thereon, which Party will control filing, prosecution and maintenance of such patents and how to pay for the filing, prosecution and maintenance of such patents. It is presumed that ImmunoGen will control filing, prosecution and maintenance of Joint Patent Rights claiming Joint Program Technology or Joint Conjugation Probody Platform Improvements, and that CytomX will control filing, prosecution and maintenance of Joint Patent Rights claiming Joint Unconjugated Probody Platform Improvements. Neither Party will file any Joint Patent Right without the prior written consent of the other Party, which consent shall not be unreasonably withheld, conditioned or delayed. The Party controlling filing and prosecution of any such Joint Patent Right (a) shall keep the other Party informed regarding each Patent Right, (b) shall consider in good faith any recommendations made by the other Party in regard to the filing, prosecution or maintenance of any such Patent Right and (c) shall not unreasonably refuse to incorporate any recommendations made by the other Party in regard to such filing, prosecution or maintenance.

  • Assignment of Patents Executive shall disclose fully to the Company any and all discoveries he shall make and any and all ideas, concepts or inventions he shall conceive or make that are related or applicable to the Business of the Company or of any of its Subsidiaries or to any other products, services, or technology in medicine or the health sciences in which the Company shall during the Employment Period undertake, or actively and in good faith consider, research or commercial involvement; provided, however, that either (a) such discovery(ies), idea(s), concept(s) and/or invention(s) are made by the Executive during the Employment Period or (b) such discovery(ies), idea(s), concept(s) and/or invention(s) are made by the Executive during the period of six (6) months after his employment terminates and are in whole or in part the result of his work with the Company. Such disclosure is to be made promptly after each such discovery or conception, and each such discovery, idea, concept or invention will become and remain the property of the Company, whether or not patent applications are filed thereon. Upon the request and at the expense of the Company, the Executive shall (i) make application through the patent solicitors of the Company for letters patent of the United States and any and all other countries at the discretion of the Company on such discoveries, ideas and inventions, and (ii) assign all such applications to the Company, or at its order, without additional payment by the Company except as otherwise agreed by the Company and the Executive. The Executive shall give the Company, its attorneys and solicitors, reasonable assistance in preparing and prosecuting such applications and, on request of the Company, execute such papers and do such things as shall be reasonably necessary to protect the rights of the Company and vest in it or its assigns the discoveries, ideas or inventions, applications and letters patent herein contemplated. Said cooperation shall also include such actions as are reasonably necessary to aid the Company in the defense of its rights in the event of litigation. This Section 18 shall not apply to any invention for which no equipment, supplies, facilities, or trade secret information of the Company or its Subsidiaries was used, and which was developed entirely on the Executive’s own time, unless (i) the invention relates directly to the Business of the Company or of any of its Subsidiaries or to the actual or demonstrably anticipated research or development of the Company or of any of its Subsidiaries, or (ii) the invention results from any work performed by the Executive for the Company.

  • Third Party Patent Rights No Party makes any warranty with respect to the validity, perfection or dominance of any Patent or other proprietary right or with respect to the absence of rights in Third Parties which may be infringed by the manufacture or sale of the Licensed Product. Each Party agrees to bring to the attention of the other Party any patent or patent application it discovers, or has discovered, and which relates to the subject matter of this Agreement.

  • INTELLECTUAL PROPERTY RIGHTS - INVENTION AND PATENT RIGHTS A. General 1. NASA has determined that 51 U.S.C. § 20135(b) does not apply to this Agreement. Therefore, title to inventions made (conceived or first actually reduced to practice) under this Agreement remain with the respective inventing party(ies). No invention or patent rights are exchanged or granted under this Agreement, except as provided herein.

  • Prosecution of Patents (a) Licensed [***] Patents, Licensed Product Improvement Patents, and Joint Patents relating to Licensed Products. Except as otherwise provided in this Section 12.3(a), as between the Parties, Takeda shall have the sole right and authority to prepare, file, prosecute and maintain the Licensed [***] Patent, Licensed Product Improvement Patents, and, where relating to Licensed Products, Joint Patents (collectively, the “[***] Patent Prosecution”) on a worldwide basis (including the right to defend in patent office proceedings such as inter partes reviews, post grant reviews and oppositions).Takeda shall bear all costs of preparation, filing, prosecution and maintenance of the [***] Patent Prosecution in the Territory. Provided that Ultragenyx’s rights with respect to the applicable Licensed Product have not terminated, Takeda, upon Ultragenyx’s request, shall provide Ultragenyx a reasonable opportunity to review and comment on material communications from any patent authority in the Territory regarding the [***] Patent Prosecution and drafts of any material filings or responses to be made to such patent authorities in advance of submitting such filings or responses. Takeda shall consider Ultragenyx’s comments regarding such communications and drafts in good faith with a view to maximizing the Patent protection and scope in the Territory in the Ultragenyx Field. If Ultragenyx’s rights with respect to the applicable Licensed Product have not terminated and Takeda determines in its sole discretion to abandon or not maintain any Licensed [***] Patent, Licensed Product Improvement Patent, or, where relating to Licensed Products, Joint Patent that is being prosecuted or maintained by Takeda in the Territory and that is applicable to the in the Ultragenyx Field, then Takeda shall provide Ultragenyx with written notice of such determination within a period of time reasonably necessary to allow Ultragenyx to determine, in its sole discretion, its interest in such Patent(s) (which notice by Takeda shall be given no later than sixty (60) days prior to the final deadline for any pending action or response that may be due with respect to such Patent(s) with the applicable patent authority). If Ultragenyx provides timely written notice expressing its interest in continuing to support such Patent(s), Ultragenyx shall have the right to pursue the filing or support the continued prosecution or maintenance of such Patents and Takeda shall provide to Ultragenyx, subject to reimbursement of Takeda’s out-of-pocket costs, all unpublished patent applications and any other information and documents necessary to permit Ultragenyx to take such action to establish or preserve any such Patents. If Ultragenyx pursues the filing or support of such Patents and Takeda continues to pursue a Licensed [***] Product in the Takeda Field, it shall provide Takeda a reasonable opportunity to review and comment on material communications from any patent authority in the Territory regarding such Patents and drafts of any material filings or responses to be made to such patent authorities in advance of submitting such filings or responses. Ultragenyx shall consider Takeda’s comments regarding such communications and drafts in good faith.

Draft better contracts in just 5 minutes Get the weekly Law Insider newsletter packed with expert videos, webinars, ebooks, and more!